$PFE Pfizer: Ibrance peak sales could exceed over $13B

From this article about Jefferies raising their PFE price target to $45:

"Early surveys show that Ibrance will beat consensus revenue estimates as it is expected to be one of the fastest oncology product launches ever. Jefferies said that PEAK SALES COULD EXCEED OVER $13 BILLION."

As I previously noted in this article, previous estimates topped out at about $6 billion ... less than half of this new high estimate.

Submitted March 23, 2015 at 10:11AM by dag_1996 http://ift.tt/1ChzypJ